Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.
about
Pneumococcal vaccine for preventing Streptococcus pneumoniae infection in HIV-infected individualsPneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of agePneumococcal vaccines for preventing otitis mediaSafety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein--conjugated pneumococcal vaccine in Filipino infantsSalivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experienceChanging epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United StatesIndirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household membersA longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar borderThe prevalence and risk factors for pneumococcal colonization of the nasopharynx among children in Kilifi District, KenyaEffect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trialVariable host-pathogen compatibility in Mycobacterium tuberculosisContribution of vaccines to our understanding of pneumococcal disease.Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines.Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure dataPrevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins.An individual-based network model to evaluate interventions for controlling pneumococcal transmission.Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adultsKinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children BrazilEpidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal diseaseSafety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trialWhich pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigenPopulation-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, BrazilPneumococcal carriage in children in The Netherlands: a molecular epidemiological study.Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art reviewSerological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection.Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse modelPriming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Serotype replacement in disease after pneumococcal vaccinationNew pneumococcal vaccines for children.Inhibition of T cells provides protection against early invasive pneumococcal diseasePneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine
P2860
Q24186767-E551B0B2-5F31-443C-872B-2DA81FF2A69AQ24245934-8EBACEB8-CF76-4850-AD22-3798E390A638Q24247465-CDF10C39-6573-48AF-B374-0522F7CE9398Q24795590-A30CA9F3-C7AF-4402-8F04-F586A05E2033Q24812739-B3C7F8DB-15FE-4663-B466-9EF70CE76515Q28088507-03C16D9E-2D76-4EB5-AE91-0D36BF9BF575Q28277609-06114DC3-8BF2-44B3-957B-390E715E1713Q28293473-EDE21E2E-A674-468A-B530-685BA3E5EFC6Q28729014-8F08F226-FBA7-401B-A5B4-73BF1C9D4CE1Q28731923-C7BC9067-019D-4FE3-B2C6-2D3797B4D353Q28743762-F68398FB-D618-42DF-8D11-350D1752429EQ28768257-39347D43-8225-4D34-AFE7-50E6F52B8A41Q30406750-DE6E70F3-4EA4-41BA-9450-1B0A5A45CE37Q30665602-BE92D4CF-AE7A-4057-A354-6837708580D4Q31158788-1ABE7C7C-97EF-4F39-A91A-80BF056EFE8DQ33202131-DA190772-B283-4D4B-823C-D93E5719D630Q33344262-815B72AE-D62A-4E88-B5CF-9CC84D8F5467Q33528283-52F982B7-4633-40D4-BCFD-699EE0BD9CDDQ33530554-CDAF19E7-FB3D-4F22-B9C1-65654E5E3B5FQ33557154-8F72EB39-23AB-4F35-91A4-49844860FC08Q33706645-A43C9C54-2642-4B06-A2AC-A08E09471D19Q33726286-A3C09A1D-CB4C-4A36-8370-B8552B6578E6Q33803550-1801E595-E07A-4F20-A517-494910E676CEQ33848675-EA86C7AA-091B-489B-B007-00395176F8E4Q33885483-5AA596F3-B84C-43B9-A62D-E1CEA24385B6Q33885487-ACF87252-78C5-4263-8AEC-55178899D7F2Q33921859-0F94F9AE-F281-41F4-B761-A3F331B352D9Q33946170-70DE0B0A-B53D-4747-A5BF-AC07BF67795AQ33973455-72689BAD-99A3-4C7C-A891-FBD11005971DQ33975684-F088D2CA-1D77-4B18-BFE9-AAFA50E6353AQ34006352-60085061-C6C9-4E2B-9E63-ABEDFC1FAC16Q34006372-3A776BDF-D64A-462C-AFD6-674429E58AEDQ34033275-9295E795-E0D6-48F2-B011-6F67740E2CCAQ34072420-770EE035-5533-473B-AE0A-CB390892C0A9Q34092415-9949CCB9-CEBD-41A3-9366-7B4FEE37B472Q34170021-4F29922E-CFD8-4402-93C8-8111F55F72BBQ34178363-EB65B271-D745-460C-B2D5-CCA19656CE13Q34190093-F7173FA6-D929-45AF-9F86-476B5C8EC821Q34309777-6722E386-2B17-403C-AAB7-5B7A1839FBA7Q34391186-40986EA2-EAB1-4982-A276-6932F5212B19
P2860
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@en
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@nl
type
label
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@en
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@nl
prefLabel
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@en
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@nl
P2093
P356
P1476
Immunogenicity and impact on n ...... neumococcal conjugate vaccine.
@en
P2093
P304
P356
10.1086/315009
P407
P577
1999-10-01T00:00:00Z